4.7 Article

Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension

Journal

JCI INSIGHT
Volume 6, Issue 10, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.145346

Keywords

-

Funding

  1. UK NIHR Clinician Scientist Fellowship [NIHR-CS-011-028]
  2. UK Medical Research Council UK [MR/K015184/1]
  3. Midlands Neuroscience Teaching and Research Fund
  4. Sir Jules Thorn Award for Biomedical Research
  5. Wellcome Trust Senior Research Fellowship [104612/Z/14/Z]
  6. RD Lawrence Fellowship (Diabetes UK)
  7. MRC [MR/P011462/1, MR/K015184/1] Funding Source: UKRI

Ask authors/readers for more resources

This study found that idiopathic intracranial hypertension (IIH) is a metabolic disorder characterized by dysfunction of adipose tissue. Patients with IIH exhibit insulin and leptin resistance, along with other metabolic abnormalities such as preferential central adiposity.
BACKGROUND. Idiopathic intracranial hypertension (IIH) is a condition predominantly affecting obese women of reproductive age. Recent evidence suggests that IIH is a disease of metabolic dysregulation, androgen excess, and an increased risk of cardiovascular morbidity. Here we evaluate systemic and adipose specific metabolic determinants of the IIH phenotype. METHODS. In fasted, matched IIH (n = 97) and control (n = 43) patients, we assessed glucose and insulin homeostasis and leptin levels. Body composition was assessed along with an interrogation of adipose tissue function via nuclear magnetic resonance metabolomics and RNA sequencing in paired omental and subcutaneous biopsies in a case-control study. RESULTS. We demonstrate an insulin- and leptin-resistant phenotype in IIH in excess of that driven by obesity. Adiposity in IIH is preferentially centripetal and is associated with increased disease activity and insulin resistance. IIH adipocytes appear transcriptionally and metabolically primed toward depot-specific lipogenesis. CONCLUSION. These data show that IIH is a metabolic disorder in which adipose tissue dysfunction is a feature of the disease. Managing IIH as a metabolic disease could reduce disease morbidity and improve cardiovascular outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available